Corpus Intelligence IC Memo — FALMOUTH HOSPITAL 2026-04-26 03:43 UTC
IC Memo — FALMOUTH HOSPITAL
Investment Committee Memorandum | MA | 81 beds | Grade C | EBITDA uplift $12.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

FALMOUTH HOSPITAL

CCN 220135 | BARNSTABLE, MA | 81 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

FALMOUTH HOSPITAL is a 81-bed suburban community hospital in BARNSTABLE, MA with $172.1M in net patient revenue and a -2.2% operating margin. The hospital serves a payer mix of 60.9% Medicare, 6.3% Medicaid, and 32.8% commercial.

Thesis: Turnaround. Our ML models identify $12.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -2.2% to 5.2% (+736bps).

Net Revenue HCRIS$172.1M
Current EBITDA COMPUTED$-3.7M
Operating Margin COMPUTED-2.2%
Occupancy HCRIS72.2%
Revenue / Bed COMPUTED$2.1M
Net-to-Gross HCRIS35.7%
Distress Probability ML44.2%

2. Market Context & Competitive Position

99
MA Hospitals
-12.2%
State Median Margin
48
Comparable Hospitals

MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -2.2% places it above the state median. Among 48 size-comparable peers (40-162 beds), the median margin is -11.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (40-162), prioritizing same-state peers. 48 hospitals in the comp set.

HospitalStateBedsRevenueMargin
FALMOUTH HOSPITAL (Target)MA81$172.1M-2.2%
BETH ISRAEL DEACONESS - PLYMOUMA150$349.1M2.6%
FAULKNER HOSPITALMA147$316.6M-7.9%
EMERSON HOSPITALMA111$315.1M-10.1%
THE MERCY HOSPITALMA150$276.4M-12.5%
MASSACHUSETTS EYE AND EAR INFIMA41$263.9M-36.1%
MILFORD REGIONAL MEDICAL CENTEMA148$254.6M-7.2%
COOLEY DICKINSON HOSPITALMA118$233.6M2.3%
STURDY MEMORIAL HOSPITALMA125$221.7M-12.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $12.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$3.6M+210bp18mo
Cost to Collect4.5%2.5%$3.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$3.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.1M+122bp9mo
Clean Claim Rate88.0%96.0%$110K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$3.6M
Cost to Collect
$3.4M
Denial Rate Reduction
$3.4M
A/R Days Reduction
$2.1M
Clean Claim Rate
$110K
Total EBITDA Uplift$12.7M
Current EBITDA$-3.7M
+ RCM Uplift+$12.7M
Pro Forma EBITDA$8.9M
Current Margin-2.2%
Pro Forma Margin5.2%
WC Released (1x)$6.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-5.7M$102.1M0.00x-100.0%
Base (11x exit)10.0x11.0x$-5.7M$110.5M0.00x-100.0%
Bull Case9.0x11.0x$-5.2M$150.4M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-5.2M$162.6M0.00x-100.0%
Bear Case11.0x10.0x$-6.3M$40.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-6.3M$42.6M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumHeavy Medicare dependenceMedicare comprises 60.9% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 48 hospitals with 40-162 beds
  • Same-state prioritization (n=49)
  • Comp margins: P25=-18.6% / P50=-11.3% / P75=2.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.